All things considered, these results revealed a novel GAS5-mediated mechanism behind the onset of NAFLD and indicated that GAS5 might be a viable target for NAFLD treatment. This evidence concerns the gene GAS5 and metabolic dysfunction-associated steatotic liver disease.